First Trimester Prediction of Preeclampsia and Fetal Growth Restriction
Status: | Recruiting |
---|---|
Conditions: | Women's Studies, Women's Studies |
Therapuetic Areas: | Reproductive |
Healthy: | No |
Age Range: | 18 - 50 |
Updated: | 4/21/2016 |
Start Date: | March 2013 |
End Date: | July 2019 |
Contact: | Jiri D Sonek, MD |
Phone: | 937 208 4005 |
First Trimester Prediction of Preeclampsia and Fetal Growth Restriction Using Uterine Artery Doppler, Maternal Blood Pressure, Maternal Characteristics, Placental Volume and Maternal Serum Factors
To evaluate the feasibility of screening for preeclampsia and fetal growth restriction
between 11-13+6 weeks' gestation utilizing the combination of uterine artery doppler,
maternal blood pressure, maternal characteristics, placental volume, and maternal serum
factors, including PAPPA-A, PLGF, AFP and free Beta HCG. This is a non interventional study.
between 11-13+6 weeks' gestation utilizing the combination of uterine artery doppler,
maternal blood pressure, maternal characteristics, placental volume, and maternal serum
factors, including PAPPA-A, PLGF, AFP and free Beta HCG. This is a non interventional study.
Preeclampsia (PE) is a condition which affects approximately 2% of all pregnancies and can
be a major cause of maternal and perinatal morbidity/mortality (2). The suspected underlying
mechanism of PE is thought to be impaired trophoblastic invasion of the maternal spiral
arteries leading to impaired placental perfusion, placental ischemia and subsequent
development of endothelial dysfunction (3). There is evidence that PE, which is commonly
associated with fetal growth restriction, can be predicted effectively at 11-13 weeks
gestational age by combined screening algorithms combining uterine artery pulsatility index
(PI), maternal mean arterial pressure (MAP) and maternal serum concentrations of placental
products including but not limited to plasma protein A (PAPP-A), and placental growth factor
(PLGF) (4-6).
Aim of Study/Hypothesis:
The aim of this study is to develop an algorithm based on the combination of maternal
factors, uterine artery pulsatility index, mean arterial pressure, placental volume and
serum biomarkers to estimate patient specific risks for the development of Preeclampsia in a
US population.
be a major cause of maternal and perinatal morbidity/mortality (2). The suspected underlying
mechanism of PE is thought to be impaired trophoblastic invasion of the maternal spiral
arteries leading to impaired placental perfusion, placental ischemia and subsequent
development of endothelial dysfunction (3). There is evidence that PE, which is commonly
associated with fetal growth restriction, can be predicted effectively at 11-13 weeks
gestational age by combined screening algorithms combining uterine artery pulsatility index
(PI), maternal mean arterial pressure (MAP) and maternal serum concentrations of placental
products including but not limited to plasma protein A (PAPP-A), and placental growth factor
(PLGF) (4-6).
Aim of Study/Hypothesis:
The aim of this study is to develop an algorithm based on the combination of maternal
factors, uterine artery pulsatility index, mean arterial pressure, placental volume and
serum biomarkers to estimate patient specific risks for the development of Preeclampsia in a
US population.
Inclusion Criteria:
All patients during their first trimester visit
Exclusion Criteria:
Fetal anomalies Pregnancies ending in termination, miscarriage or fetal death prior to 22
weeks and cases with no pregnancy follow up.
We found this trial at
1
site
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
Click here to add this to my saved trials